跳至主要内容
临床试验/KCT0009216
KCT0009216尚未招募Unknown

The Clinical Impact of Magnesium Sulfate Administration before the Cerebral Aneurysm Clipping Surgery: A Prospective Multicenter Randomized Blinded Study

Asan Medical Center0 个研究点目标入组 398 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
入组人数
398

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19(Year) 至 75(Year)(—)
性别
All

入选标准

  • 1.Age =19 years and = 75 years
  • 2.Patient undergoing surgery (craniotomy) for either unruptured or ruptured (= subarachnoid hemorrhage, SAH) intracranial aneurysms and subsequently admitted to the ICU
  • 3.Glasgow coma score (GCS): 9~ 15 (able to answer the post-operative pain scale questionnaire)

排除标准

  • 1Pre-operative serum magnesium level below or above the normal range (1.8 – 3mg/dL)
  • 2History (within 6 months) or currently taking oral magnesium supplementation
  • 3Concurrent medical illnesses resulting in severe pain prior to surgery, for which the patient is receiving pain-relief medication (such as migraine, cluster headache, gout, fibromyalgia, spinal disease and etc.)
  • 4At high nutritional risk (Nutritional Risk Screening 2002 version = 5)
  • 5Current or history of long term total enteral or parenteral nutrition (TPN) use
  • 6Unstable vital signs requiring the use of vasoactive agents
  • 7Concomitant medical illness that may interfere with the study outcome assessments (can cause hypomagnesemia)
  • 7.1Renal: alcoholism, diabetes, ketoacidosis, tubular defects (renal tubular acidosis, Welt syndrome, Gitelman syndrome and etc.), hyperthyroidism, hypoparathyroidism, hyperaldosteronism, hypercalcemia, hypophosphatemia
  • 7.2Gastro-intestinal: diarrhea or vomiting, dietary deficiency (including protein – calorie malnutrition, parental and enteral feeding with inadequate magnesium), familial magnesium malabsorption, GI fistula, inflammatory bowel disease, refeeding syndrome, laxative abuse, magnesium malabsorption (chronic pancreatitis), nasogastric suction, surgical resection
  • 7.3Shifts from extracellular to intracellular fluids: blood transfusion (massive), epinephrine, acidosis, hungry bone syndrome, acute pancreatitis
  • 7.4Transdermal loss: excessive sweating, massive burns
  • 7.5The current electrolyte imbalances: hypokalemia, hypercalcemia, etc.
  • 7.6Systemic malignant tumor (brain, lung, gastric, colon, liver, breast and etc.)
  • 7.7Post-anoxic coma; status epilepticus without underlying brain injury; central nervous system (CNS) infections (community-acquired; hospital-acquired; ventriculitis; post-operative)
  • 8Taking medication that can cause hypomagnesemia
  • Diuretics: thiazide, loop, K-sparing diuretics and etc.
  • Antibiotics/antifungal: aminoglycoside, amphotericin B, gentamycin and etc.
  • Digoxin, cisplatin, tacrolimus, pentamidine, proton pump inhibitor (PPI)
  • 9Administrating magnesium content fluid (e.g., plasm-lyte, plasma solution and etc.)
  • 10Neuromuscular disease like myasthenia gravis
  • 11History of gastric or bowel surgery
  • 12Arrhythmia (AV block, sinus bradycardia and etc.)
  • 13Allergic to magnesium sulfate
  • 14Pregnancy
  • 15GCS < 6; brain death or imminent death (within 72 hours)
  • 16DNR (do not resuscitate) ordered patient
  • 17Currently participating in other investigational trials

研究者

相似试验